| Autor: |
M. Shann Wilson, Erik W. Thompson |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Journal of Clinical and Translational Endocrinology Case Reports, Vol 3, Iss , Pp 1-5 (2017) |
| Druh dokumentu: |
article |
| ISSN: |
2214-6245 |
| DOI: |
10.1016/j.jecr.2016.10.002 |
| Popis: |
Aims/Hypothesis: Previous studies have associated serum ferritin levels with type 2 diabetes, so it's well recognised that there is a subset of patients with type 2 diabetes and also with elevated serum ferritin. The aim of this pilot study was to test whether venesection is a viable treatment option for patients with type 2 diabetes. Methods: Four cases with elevated serum ferritin and type 2 diabetes were subjected to monthly venesection for 3–9 months, and monitored 3 monthly for serum ferritin and glycated haemoglobin (HbA1c). Results: In all four cases, serum ferritin was dramatically reduced, and the HbA1c was reduced in all but one case, which was a diet-only controlled patient with diabetes and had near normal HbA1c. In two cases, HbA1c was reduced by 2–3% units (22–33 mmol/mol), making it superior to any current medication. Conclusions/Interpretation: Venesection was used here successfully with oral pharmacotherapy, thereby avoiding the use of insulin. Findings of this study may provide clinicians a powerful new tool to intervene in the pathological process of type 2 diabetes by a very simple manoeuvre - venesection. These results need to be repeated and validated in a larger trial as a priority. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
